Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANT Squamous Cell Carcinoma Vaccine
- Development stage
- Discontinued
- Lead developer
- ImmunityBio
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
**NANT Squamous Cell Carcinoma Vaccine** is an investigational, molecularly informed multi-agent cancer-immunotherapy regimen developed for advanced squamous cell carcinomas progressing after platinum-based chemotherapy and PD-1 or PD-L1 blockade. The QUILT-3.090 protocol combined metronomic chemotherapy and tumor-directed treatment with adenoviral and recombinant yeast cancer vaccines, the IL-15 superagonist nogapendekin alfa inbakicept, and allogeneic high-affinity natural killer cells. Vaccine elements were designed to elicit antigen-specific T-cell responses against carcinoembryonic antigen, HER2, brachyury, MUC1, and mutant RAS, while the broader regimen aimed to augment innate NK-cell and adaptive antitumor immunity. It was investigated in squamous cell carcinoma, including head and neck squamous cell carcinoma and squamous non-small cell lung cancer, but is not an approved product.
- Brand names
- Nant HNSCC Vaccine
- Other names
- NANT SCC VaccineNANT Squamous Cell Carcinoma (SCC) VaccineNANT Squamous Cell Carcinoma Vaccine
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on NANT Squamous Cell Carcinoma Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANT Squamous Cell Carcinoma Vaccine.